PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29948358-1	2018	Sorafenib has been widely used to treat unresectable hepatocellular carcinoma (HCC) but most studies have been done in Child-Pugh A (CP-A) patients with well-preserved liver function.	Sorafenib	0-9	carboxypeptidase A1	Homo sapiens	133-137	
29188773-10	2017	Mean pharmacokinetic exposure to Sorafenib tosylate 200 mg, Ribavirn and Sofosbuvir at week 8th was 2.1, 1.5,1.2 times greater in CP B than in CP A.	Sorafenib	33-42	carboxypeptidase A1	Homo sapiens	143-147	
29188773-8	2017	Child pugh score less then 7 (CP A) in adults during treatment phase (received 12 weeks of Sorafenib tosylate 200 mg, Ribavirn and Sofosbuvir 400 mg once daily) have no side effect while child pugh score 7-9 (CP B) have evidence of hypertension.	Sorafenib	91-109	carboxypeptidase A1	Homo sapiens	30-34	
26029452-11	2015	CONCLUSIONS: Patients with CP-A or CP-B advanced HCC should be offered sorafenib at 400 mg twice daily with optimal management of AEs in order to improve survival.	Sorafenib	71-80	carboxypeptidase A1	Homo sapiens	27-31	
25789012-3	2015	The present study describes the use of sorafenib in patients with HCC and CP-A or -B cirrhosis.	Sorafenib	39-48	carboxypeptidase A1	Homo sapiens	74-84	
21883324-9	2011	In the sorafenib group, median OS according to baseline AST was 11.8 (<100 U/L [n = 58]) vs. 3.9 (>=100 U/L [n = 15]) months for CP-A patients (P = 0.127), and 6.5 (<100 U/L [n = 33]) vs. 2.1 (>=100 U/L [n = 21]) months for CP-B patients (P = 0.011).	Sorafenib	7-16	carboxypeptidase A1	Homo sapiens	135-139	
21883324-11	2011	CONCLUSIONS: Sorafenib was associated with improved survival in both CP-A and CP-B patients.	Sorafenib	13-22	carboxypeptidase A1	Homo sapiens	69-73